IN2012DN00754A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00754A IN2012DN00754A IN754DEN2012A IN2012DN00754A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A IN 754DEN2012 A IN754DEN2012 A IN 754DEN2012A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A
- Authority
- IN
- India
- Prior art keywords
- compounds
- antagonists
- lpa
- medicaments
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23128209P | 2009-08-04 | 2009-08-04 | |
| PCT/US2010/044284 WO2011017350A2 (en) | 2009-08-04 | 2010-08-03 | Compounds as lysophosphatidic acid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00754A true IN2012DN00754A (el) | 2015-06-19 |
Family
ID=43544907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN754DEN2012 IN2012DN00754A (el) | 2009-08-04 | 2010-08-03 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8592402B2 (el) |
| EP (1) | EP2462128B1 (el) |
| JP (1) | JP2013501064A (el) |
| CN (1) | CN102574822A (el) |
| IN (1) | IN2012DN00754A (el) |
| WO (1) | WO2011017350A2 (el) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455499B2 (en) | 2008-12-11 | 2013-06-04 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| BR112013014019A2 (pt) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
| JP2014513077A (ja) | 2011-04-05 | 2014-05-29 | アミラ ファーマシューティカルス，インコーポレーテッド | 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| JP5978302B2 (ja) * | 2011-08-08 | 2016-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | リゾホスファチジン酸アンタゴニストとしての（ｎ−ベンズイミダゾール−２−イル）−シクロプロパンカルボキサミド |
| CN104066729A (zh) * | 2011-08-15 | 2014-09-24 | 英特穆恩公司 | 溶血磷脂酸受体拮抗剂 |
| WO2013078283A1 (en) | 2011-11-22 | 2013-05-30 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
| AU2013276617B9 (en) | 2012-06-13 | 2018-03-29 | F. Hoffmann-La Roche Ag | New diazaspirocycloalkane and azaspirocycloalkane |
| WO2013189862A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Substituted pyrazole compounds as lpar antagonists |
| WO2014026039A2 (en) * | 2012-08-09 | 2014-02-13 | Neuropore Therapies, Inc. | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
| SI2900669T1 (sl) | 2012-09-25 | 2019-12-31 | F. Hoffmann-La Roche Ag | Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic |
| RU2649398C2 (ru) | 2012-12-28 | 2018-04-03 | Убе Индастриз, Лтд. | Галогензамещенное гетероциклическое соединение |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| SG10201803833WA (en) | 2013-03-15 | 2018-06-28 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| GB201314926D0 (en) * | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| MY187449A (en) | 2013-11-26 | 2021-09-22 | Hoffmann La Roche | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| DK3122750T3 (da) | 2014-03-26 | 2019-11-04 | Hoffmann La Roche | Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere |
| PE20161223A1 (es) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| SG11201607920RA (en) | 2014-04-04 | 2016-10-28 | X Rx Inc | Substituted spirocyclic inhibitors of autotaxin |
| WO2015175171A1 (en) * | 2014-04-23 | 2015-11-19 | X-Rx Discovery, Inc. | Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases |
| KR102433588B1 (ko) | 2014-06-27 | 2022-08-19 | 우베 가부시키가이샤 | 할로겐 치환 헤테로환 화합물의 염 |
| WO2016046782A1 (en) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Imidazole biaryl compounds as s-nitrosoglutathione reductase inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CN113651873A (zh) * | 2015-05-01 | 2021-11-16 | Onl医疗股份有限公司 | 肽组合物和使用方法 |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フェノキシメチル誘導体 |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112018006024A2 (pt) | 2015-09-24 | 2020-05-12 | F. Hoffmann-La Roche Ag | Compostos bicíclicos como inibidores de atx |
| CN107614505B (zh) | 2015-09-24 | 2021-05-07 | 豪夫迈·罗氏有限公司 | 作为双重atx/ca抑制剂的新型二环化合物 |
| MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| MX2020004202A (es) | 2017-10-30 | 2020-08-13 | Neuropore Therapies Inc | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. |
| KR20200100752A (ko) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산 |
| HRP20211918T8 (hr) | 2017-12-19 | 2022-04-15 | Bristol-Myers Squibb Company | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti |
| CN111479807A (zh) * | 2017-12-19 | 2020-07-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑吖嗪 |
| BR112020011965A2 (pt) | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | triazol azinas de ácido ciclo-hexílico como antagonistas de lpa |
| EP3727589B1 (en) | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| EP3728242B1 (en) * | 2017-12-19 | 2023-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CN111712492B (zh) | 2017-12-19 | 2024-05-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸三唑唑类 |
| WO2019126089A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| JP7465899B2 (ja) | 2019-06-18 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸 |
| US20220235026A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
| US20220235040A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Isoxazole carboxylic acids as lpa antagonists |
| WO2021020429A1 (ja) * | 2019-07-30 | 2021-02-04 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物 |
| KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556A (zh) | 2020-06-03 | 2023-03-28 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| CA3185111A1 (en) * | 2020-07-16 | 2022-01-20 | Elisabetta Armani | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| DE69720773T2 (de) | 1996-12-23 | 2004-01-29 | Bristol Myers Squibb Pharma Co | SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER |
| JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| WO2001060819A1 (fr) | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| ATE406915T1 (de) | 2001-07-17 | 2008-09-15 | Ono Pharmaceutical Co | Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| JP4569106B2 (ja) | 2001-12-25 | 2010-10-27 | 味の素株式会社 | 臓器線維化抑制剤 |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| WO2003094965A2 (en) | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| US7229987B2 (en) | 2002-05-13 | 2007-06-12 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| AU2003241833A1 (en) | 2002-05-28 | 2003-12-12 | Ono Pharmaceutical Co., Ltd. | Beta-ALANINE DERIVATIVE AND USE THEREOF |
| JPWO2004002530A1 (ja) | 2002-06-26 | 2005-10-27 | 小野薬品工業株式会社 | 慢性疾患治療剤 |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| EP1570081A4 (en) | 2002-11-19 | 2006-05-31 | Amgen Inc | AMPLIFIED GENES INVOLVED IN CANCER |
| US20040192739A1 (en) | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
| US20040167132A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| US20050065194A1 (en) | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
| US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| US7115642B2 (en) | 2003-05-02 | 2006-10-03 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection |
| ES2379169T3 (es) | 2003-05-19 | 2012-04-23 | Irm Llc | Composiciones y compuestos inmunosupresores |
| WO2007016784A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| ATE528276T1 (de) | 2003-12-19 | 2011-10-15 | Ono Pharmaceutical Co | Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen |
| DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
| JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤 |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| KR20080047410A (ko) | 2005-08-23 | 2008-05-28 | 아이알엠 엘엘씨 | 면역억제제 화합물 및 조성물 |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
| WO2007096647A2 (en) | 2006-02-27 | 2007-08-30 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| WO2008024979A2 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| US20080051372A1 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| US20100143381A1 (en) | 2007-03-12 | 2010-06-10 | Andrew Tager | Lysophosphatidic acid receptor targeting for lung disease |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| NZ588807A (en) | 2008-05-05 | 2011-07-29 | Sanofi Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| US8455499B2 (en) | 2008-12-11 | 2013-06-04 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2010
- 2010-08-03 EP EP10807045.9A patent/EP2462128B1/en not_active Not-in-force
- 2010-08-03 WO PCT/US2010/044284 patent/WO2011017350A2/en active Application Filing
- 2010-08-03 CN CN2010800429638A patent/CN102574822A/zh active Pending
- 2010-08-03 US US13/388,502 patent/US8592402B2/en active Active
- 2010-08-03 JP JP2012523709A patent/JP2013501064A/ja active Pending
- 2010-08-03 IN IN754DEN2012 patent/IN2012DN00754A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8592402B2 (en) | 2013-11-26 |
| CN102574822A (zh) | 2012-07-11 |
| WO2011017350A2 (en) | 2011-02-10 |
| US20120196839A1 (en) | 2012-08-02 |
| EP2462128A4 (en) | 2012-10-03 |
| WO2011017350A3 (en) | 2011-06-30 |
| EP2462128A2 (en) | 2012-06-13 |
| JP2013501064A (ja) | 2013-01-10 |
| EP2462128B1 (en) | 2016-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02177A (el) | ||
| IN2012DN02702A (el) | ||
| IN2012DN00754A (el) | ||
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| WO2010077883A3 (en) | Antagonists of lysophosphatidic acid receptors | |
| PH12015501737B1 (en) | Androgen receptor modulators and uses thereof | |
| MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
| WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| WO2011156518A3 (en) | Estrogen receptor modulators and uses thereof | |
| GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
| MY162604A (en) | Heterocyclic compounds and uses thereof | |
| IN2012DN02471A (el) | ||
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |